@Marc Libretto The guy who published that video you are quoting was wrong. The label itself even warns that EGRIFTA WR and SV (earlier formulation) are not substitutable, specifically because their reconstitution and storage requirements differ . Most gray-market or research peptides lack cyclodextrin stabilization, so refrigeration becomes your only line of defense against hydrolysis and oxidation.

@Marc Libretto this is a great example of why the peptide space gets a lot of heat from the Pharma industry. If you read the label this product formulation was specifically engineered so refrigeration adds no benefit and may actually introduce instability (temperature cycling, condensation, crystallization effects). Once you factor in excipients and validated stability testing, the label makes perfect sense. This is one of those cases where the molecule didn’t change — Egrifta WR and RUO Tesamorelin have the same active ingredient - but the chemistry around it did. Remember Tesamorelin is FDA approved for HIV positive individuals with lipodystrophy - a lifetime disorder. Egrifta WR was developed to reduce user burden (weekly reconstitution + smaller injection volume) and avoid cold-chain constraints (room-temperature handling), thereby improving the day-to-day practicality of a chronic therapy used in adults with HIV. The product feature makes sense why the drug co wants to ensure better compliance by users.

We can’t be trusted to buy things for our own health. Thanks for protecting us Visa and Mastercard. Apparently there is no moral hazard in buying booze, fast food, and paying for strip clubs using your fine products (I’m being facetious to make a point).

COA is almost a year old. Should that be a concern?

@David Furka thanks, brother!

Your hyperlink is bad with a typo - heads up

Cha-Ching. Gonna try the Snap8.